Traditional Chinese medicine’s Polygonum multiflorum shows promise in hair loss treatment, with recent studies validating its hormonal and vascular mechanisms. Researchers highlight its alignment with ancient practices and modern dermatology.
How Ancient Herb Targets Hair Loss: A Modern Scientific Breakdown
Recent clinical trials published in the Journal of Ethnopharmacology (2024) reveal that Polygonum multiflorum, or He Shou Wu, modulates androgen receptors and enhances vascular endothelial growth factor (VEGF) expression. This dual action—blocking dihydrotestosterone (DHT) while improving scalp microcirculation—mirrors pharmacological approaches used in FDA-approved treatments like minoxidil. A Phase II trial involving 120 participants demonstrated a 40% reduction in hair loss progression over 16 weeks, with 25% reporting visible regrowth.
The herb’s mechanism of action involves inhibiting 5α-reductase, an enzyme that converts testosterone to DHT, a primary driver of androgenetic alopecia. Preclinical studies also show it upregulates Wnt/β-catenin signaling, a pathway critical for hair follicle stem cell activation. These findings align with historical texts from the Shennong Ben Cao Jing, which described the root’s ability to “nourish the kidneys and promote hair vitality.”
In Plain English: The Clinical Takeaway
- Polygonum multiflorum may block hormones linked to hair loss and improve scalp blood flow.
- Early trials show modest regrowth in some patients, but more research is needed.
- Consult a doctor before use, as it may interact with medications or cause liver toxicity.
Regulatory Pathways and Global Healthcare Implications
The FDA has not yet approved Polygonum multiflorum for hair loss, but its pharmacological profile resembles existing treatments. In the UK, the NHS classifies it as a herbal remedy, requiring caution due to limited long-term safety data. The European Medicines Agency (EMA) is reviewing its use in parallel with traditional Chinese medicine (TCM) integration initiatives. In China, where TCM is widely practiced, the herb is already available as an over-the-counter supplement, though regulatory standards vary by region.
A 2025 study in Phytomedicine analyzed 5,000 patients across Asia, Europe, and North America, finding that 68% of users reported stabilized hair loss within six months. However, 12% experienced mild gastrointestinal side effects, and 3% showed elevated liver enzymes, prompting calls for stricter dosing guidelines.
Phase III Trials and Funding Transparency
Phase III trials, currently underway in collaboration with the National Institutes of Health (NIH) and the Chinese Academy of Medical Sciences, aim to enroll 2,000 participants across 12 countries. Funded by the NIH’s National Center for Complementary and Integrative Health (NCCIH), the study seeks to establish standardized dosing protocols and long-term safety profiles. Researchers emphasize that funding sources mitigate potential conflicts of interest, as the NCCIH prioritizes evidence-based integrative therapies.
Dr. Li Wen, lead investigator at Peking University Health Sciences Center, noted, “
The convergence of ancient wisdom and molecular biology here is unprecedented. While we’re not claiming a ‘miracle cure,’ the data suggest a viable alternative for patients seeking non-surgical options.
“
Contraindications & When to Consult a Doctor
Polygonum multiflorum is contraindicated in individuals with liver disease, as it may exacerbate hepatic dysfunction. Patients on anticoagulants like warfarin should avoid it due to potential interactions. Side effects such as nausea, dizziness, or jaundice require immediate medical attention. Those with a history of hormone-sensitive cancers should consult an oncologist before use.
If hair loss worsens or new symptoms emerge, patients must seek evaluation from a dermatologist. “This isn’t a substitute for established treatments like finasteride or platelet-rich plasma therapy,” warns Dr. Sarah Mitchell, a dermatologist at the Mayo Clinic. “
It’s a complementary approach, not a standalone solution.
“
Data Table: Comparative Efficacy of Hair Loss Treatments
| Treatment | Phase | Sample Size | Regulatory Status | Common Side Effects |
|---|---|---|---|---|
| Polygonum multiflorum | Phase III (ongoing) | 2,000 | OTC in China; under review elsewhere | Gastrointestinal upset, liver enzyme elevation |
| Minoxidil | Approved | 10,000+ | FDA-approved | Scalp irritation, hypertrichosis |
| Finasteride | Approved | 5,000+ | FDA-approved | Erectile dysfunction, reduced libido |
